OncoTherapy Science, Inc.
4564 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 川崎市川崎区東田町１番地２
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
OncoTherapy Science, Inc. (OTS) is a Japanese biotechnology company focused on the discovery and development of molecular-targeted anti-cancer therapies. OTS has identified numerous cancer-specific genes that are critical for creating innovative treatments. The company conducts extensive medicinal research to understand the subcellular localization, functionality, and immunogenicity of these genes. In addition to drug development, OTS offers comprehensive analysis services utilizing advanced next-generation sequencing technology to assess TCR repertoires from blood and tissue samples. Committed to high efficacy and minimized adverse effects, OTS collaborates with renowned genomics expert Professor Yusuke Nakamura to advance its mission in the battle against cancer.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-26 03:49 |
Inside Information Statement
臨時報告書
|
Japanese | 21.9 KB | |
| 2025-06-24 09:11 |
Internal Control over Financial Reporting
内部統制報告書－第24期(2024/04/01－2025/03/31)
|
Japanese | 22.8 KB | |
| 2025-06-24 09:10 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2025-06-24 09:09 |
Annual Report
有価証券報告書－第24期(2024/04/01－2025/03/31)
|
Japanese | 976.0 KB | |
| 2025-04-10 08:33 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 404.8 KB | |
| 2025-02-18 01:06 |
Inside Information Statement
臨時報告書
|
Japanese | 21.4 KB | |
| 2024-11-11 01:25 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2024-11-11 01:23 |
Interim Report
半期報告書－第24期(2024/04/01－2025/03/31)
|
Japanese | 272.5 KB | |
| 2024-06-28 08:58 |
Inside Information Statement
臨時報告書
|
Japanese | 22.8 KB | |
| 2024-06-25 09:30 |
Internal Control over Financial Reporting
内部統制報告書－第23期(2023/04/01－2024/03/31)
|
Japanese | 22.9 KB | |
| 2024-06-25 09:29 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2024-06-25 09:26 |
Annual Report
有価証券報告書－第23期(2023/04/01－2024/03/31)
|
Japanese | 1007.8 KB | |
| 2024-04-05 08:07 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 368.3 KB | |
| 2024-02-16 08:53 |
Inside Information Statement
臨時報告書
|
Japanese | 22.1 KB | |
| 2024-02-13 01:17 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Antibiotice S.A. | Romania | ATB | |
|
Aran Research & Development (1982) Ltd. | Israel | ARAN | |
|
Asarina Pharma AB | Sweden | ASAP | |
| ASKA Pharmaceutical Holdings CO., Ltd. | Japan | 4886 | ||
|
Astellas Pharma Inc. | Japan | 4503 | |
|
AstraZeneca PLC | United Kingdom | AZN | |
|
Basilea Pharmaceutica AG | Switzerland | BSLN | |
|
Bayer AG | Germany | BAY | |
|
Biofarm S.A. | Romania | BIO | |
|
Biogened Spolka Akcyjna | Poland | BGD |